Jeffrey V. Matous, MD

Articles by Jeffrey V. Matous, MD

Managing A Case of Newly-Diagnosed Transplant-Ineligible MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 24th 2021

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

Managing Adequate/Inadequate Treatment Response in MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 22nd 2021

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.

MRD Testing in Multiple Myeloma

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 17th 2021

Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.

Frequency of Measuring Treatment Response in MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 15th 2021

Recommendations for measuring treatment response in patients with multiple myeloma utilizing tests such as MRD assessments.

Strategies to Monitor Multiple Myeloma

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 10th 2021

Different markers and tests that are used to monitor disease status and treatment response in patients with multiple myeloma.

Goals of Therapy for Transplant-Ineligible MM

ByRobert Z. Orlowski, MD, PhD,Larry Anderson, MD, PhD,Caitlin Costello, MD,Jeffrey V. Matous, MD

September 8th 2021

Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.

Jeffrey V. Matous, MD

Articles by Jeffrey V. Matous, MD

Managing A Case of Newly-Diagnosed Transplant-Ineligible MM

Managing Adequate/Inadequate Treatment Response in MM

MRD Testing in Multiple Myeloma

Frequency of Measuring Treatment Response in MM

Strategies to Monitor Multiple Myeloma

Goals of Therapy for Transplant-Ineligible MM

Trending on CancerNetwork

FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC

FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC

FDA Grants Priority Review to Zanubrutinib Regimen in Frontline MCL

Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths

Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC